Reston, VA—A novel prostate cancer treatment— 225 Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic ...
PSMA radioligand therapy is associated with significant reductions in PSA levels among select patients with metastatic prostate cancer, suggesting tumor responses. Prostate-specific membrane antigen ...
ORLANDO -- An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC ...
Standardized criteria in PSMA PET/CT for patient selection for 177 Lu-PSMA radionuclide therapy (RNT) have been established, but further refinement to enhance therapeutic responses is warranted.
Houston, TX, Feb. 15, 2023 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225 Ac-PSMA-I&T asset by ...
HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results